Annual CFF
-$16.34 M
-$72.58 M-129.05%
December 31, 2023
Summary
- As of February 8, 2025, UBX annual cash flow from financing activities is -$16.34 million, with the most recent change of -$72.58 million (-129.05%) on December 31, 2023.
- During the last 3 years, UBX annual CFF has fallen by -$80.22 million (-125.58%).
- UBX annual CFF is now -111.93% below its all-time high of $136.93 million, reached on December 31, 2018.
Performance
UBX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
-$68.00 K-100.00%
September 30, 2024
Summary
- As of February 8, 2025, UBX quarterly cash flow from financing activities is $0.00, with the most recent change of -$68.00 thousand (-100.00%) on September 30, 2024.
- Over the past year, UBX quarterly CFF has increased by +$18.38 million (+100.00%).
- UBX quarterly CFF is now -100.00% below its all-time high of $82.25 million, reached on June 30, 2018.
Performance
UBX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$4.46 M
+$18.38 M+132.01%
September 30, 2024
Summary
- As of February 8, 2025, UBX TTM cash flow from financing activities is $4.46 million, with the most recent change of +$18.38 million (+132.01%) on September 30, 2024.
- Over the past year, UBX TTM CFF has increased by +$23.63 million (+123.24%).
- UBX TTM CFF is now -96.75% below its all-time high of $136.93 million, reached on December 31, 2018.
Performance
UBX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
UBX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -129.1% | +100.0% | +123.2% |
| 3 y3 years | -125.6% | -100.0% | -92.1% |
| 5 y5 years | -111.9% | -100.0% | -92.1% |
UBX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -129.1% | at low | -100.0% | +100.0% | -92.8% | +123.2% |
| 5 y | 5-year | -125.6% | at low | -100.0% | +100.0% | -94.7% | +123.2% |
| alltime | all time | -111.9% | at low | -100.0% | +100.0% | -96.8% | +123.2% |
Unity Biotechnology Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $4.46 M(-132.0%) |
| Jun 2024 | - | $68.00 K(>+9900.0%) | -$13.92 M(-16.2%) |
| Mar 2024 | - | $0.00(-100.0%) | -$16.61 M(+1.7%) |
| Dec 2023 | -$16.34 M(-129.1%) | $4.39 M(-123.9%) | -$16.34 M(-14.8%) |
| Sep 2023 | - | -$18.38 M(+600.1%) | -$19.18 M(-138.8%) |
| Jun 2023 | - | -$2.63 M(-1058.0%) | $49.42 M(-5.3%) |
| Mar 2023 | - | $274.00 K(-82.3%) | $52.18 M(-7.2%) |
| Dec 2022 | $56.24 M(+169.8%) | $1.55 M(-96.9%) | $56.24 M(-8.6%) |
| Sep 2022 | - | $50.22 M(>+9900.0%) | $61.55 M(+332.5%) |
| Jun 2022 | - | $138.00 K(-96.8%) | $14.23 M(-5.8%) |
| Mar 2022 | - | $4.33 M(-36.9%) | $15.11 M(-27.5%) |
| Dec 2021 | $20.84 M(-67.4%) | $6.86 M(+136.6%) | $20.84 M(+43.8%) |
| Sep 2021 | - | $2.90 M(+184.6%) | $14.50 M(-67.4%) |
| Jun 2021 | - | $1.02 M(-89.9%) | $44.46 M(-31.5%) |
| Mar 2021 | - | $10.06 M(+1854.2%) | $64.95 M(+1.7%) |
| Dec 2020 | $63.88 M | $515.00 K(-98.4%) | $63.88 M(-24.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $32.86 M(+52.8%) | $84.23 M(+48.4%) |
| Jun 2020 | - | $21.51 M(+139.2%) | $56.78 M(+57.1%) |
| Mar 2020 | - | $8.99 M(-56.9%) | $36.15 M(+31.7%) |
| Dec 2019 | $27.44 M(-80.0%) | $20.87 M(+285.9%) | $27.44 M(+299.6%) |
| Sep 2019 | - | $5.41 M(+513.7%) | $6.87 M(+373.9%) |
| Jun 2019 | - | $881.00 K(+212.4%) | $1.45 M(-98.3%) |
| Mar 2019 | - | $282.00 K(-5.1%) | $82.82 M(-39.5%) |
| Dec 2018 | $136.93 M(+220.1%) | $297.00 K(-2800.0%) | $136.93 M(+0.2%) |
| Sep 2018 | - | -$11.00 K(-100.0%) | $136.62 M(+0.1%) |
| Jun 2018 | - | $82.25 M(+51.2%) | $136.54 M(+53.1%) |
| Mar 2018 | - | $54.39 M(<-9900.0%) | $89.18 M(+108.5%) |
| Dec 2017 | $42.77 M(-60.4%) | -$12.00 K(-86.2%) | $42.77 M(-0.0%) |
| Sep 2017 | - | -$87.00 K(-100.2%) | $42.79 M(-0.2%) |
| Jun 2017 | - | $34.89 M(+336.9%) | $42.87 M(+436.9%) |
| Mar 2017 | - | $7.99 M | $7.99 M |
| Dec 2016 | $107.94 M | - | - |
FAQ
- What is Unity Biotechnology annual cash flow from financing activities?
- What is the all time high annual CFF for Unity Biotechnology?
- What is Unity Biotechnology annual CFF year-on-year change?
- What is Unity Biotechnology quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Unity Biotechnology?
- What is Unity Biotechnology quarterly CFF year-on-year change?
- What is Unity Biotechnology TTM cash flow from financing activities?
- What is the all time high TTM CFF for Unity Biotechnology?
- What is Unity Biotechnology TTM CFF year-on-year change?
What is Unity Biotechnology annual cash flow from financing activities?
The current annual CFF of UBX is -$16.34 M
What is the all time high annual CFF for Unity Biotechnology?
Unity Biotechnology all-time high annual cash flow from financing activities is $136.93 M
What is Unity Biotechnology annual CFF year-on-year change?
Over the past year, UBX annual cash flow from financing activities has changed by -$72.58 M (-129.05%)
What is Unity Biotechnology quarterly cash flow from financing activities?
The current quarterly CFF of UBX is $0.00
What is the all time high quarterly CFF for Unity Biotechnology?
Unity Biotechnology all-time high quarterly cash flow from financing activities is $82.25 M
What is Unity Biotechnology quarterly CFF year-on-year change?
Over the past year, UBX quarterly cash flow from financing activities has changed by +$18.38 M (+100.00%)
What is Unity Biotechnology TTM cash flow from financing activities?
The current TTM CFF of UBX is $4.46 M
What is the all time high TTM CFF for Unity Biotechnology?
Unity Biotechnology all-time high TTM cash flow from financing activities is $136.93 M
What is Unity Biotechnology TTM CFF year-on-year change?
Over the past year, UBX TTM cash flow from financing activities has changed by +$23.63 M (+123.24%)